Allogene Therapeutics (ALLO) Total Current Liabilities (2017 - 2026)

Allogene Therapeutics has disclosed Total Current Liabilities across 10 years of filings, most recently posting $28.3 million for Q1 2026.

• Total Current Liabilities for Q1 2026 came in at $28.3 million, down 5.64% year-over-year; the trailing twelve-month figure through Mar 2026 was $28.3 million (down 5.64% YoY), and the FY2025 annual result was $32.5 million, down 8.47% from the prior year.
• Total Current Liabilities came in at $28.3 million for Q1 2026 at Allogene Therapeutics, down from $32.5 million in the prior quarter.
• In the past five years, Total Current Liabilities ranged from a high of $59.4 million in Q1 2023 to a low of $28.3 million in Q1 2026.
• The 5-year median for Total Current Liabilities is $36.6 million (2022), against an average of $38.9 million.
• Across the five-year window, Total Current Liabilities soared 62.21% in 2023 and slumped 47.99% in 2024, its largest moves.
• Allogene Therapeutics' Total Current Liabilities stood at $53.7 million in 2022, then sank by 30.99% to $37.1 million in 2023, then fell by 4.2% to $35.5 million in 2024, then slipped by 8.47% to $32.5 million in 2025, then dropped by 12.87% to $28.3 million in 2026.
• The last three Total Current Liabilities figures came in at $28.3 million (Q1 2026), $32.5 million (Q4 2025), and $31.8 million (Q3 2025), per Business Quant data.